You are here: Home » Current Affairs » Coronavirus » News
Patients from outside, unlocking led to rise in Covid-19 in Delhi: Experts
Govt amends CSR norms; likely to help boost funds for Covid vaccines, drugs
Business Standard

Pune: Phase 2 human trial of Oxford Covid-19 vaccine may start tomorrow

Doses of the potential coronavirus vaccine developed by researchers at Oxford University arrived at the Bharti Vidyapeeth's Medical College in Pune for phase-2 human trials

Topics
Oxford University | Coronavirus Vaccine | Coronavirus

Press Trust of India  |  Pune 



oxford, vaccine trials, coronavirus, covid-19

Doses of the potential coronavirus

vaccine developed by researchers at arrived at the Bharti Vidyapeeth's Medical College here for phase-2 human trials on Tuesday, an official said.

The trial may begin from Wednesday, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India (SII).

"To start with we have identified five volunteers who will undergo COVID-19 and antibodies test. Those whosereports are negative will be shortlisted for vaccination on Wednesday," said Dr Sanjay Lalwani, Medical Director, Bharti Vidyapeeth's Medical College and Hospital and Research Centre.

He said the hospital has been given a target of enlisting 300 to 350 volunteers. Those chosen for receiving a dose of vaccine will be in the age group of 18 to 99 years, he told PTI.

Dr Jeetendra Oswal, deputy medical director of the hospital, said after they are administered the vaccine, the volunteers will be monitored as per the standard trial protocol.

The other hospitals where trials are to be conducted include B J Medical College Hospital in Pune, AIIMS Delhi, Rajendra MemorialResearch Institute of Medical Sciences in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh,Nehru Hospital in Gorakhpur and Andhra Medical College in Visakhapatnam.

SII, the world's largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of in collaboration with British-Swedish pharma company AstraZeneca.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, August 25 2020. 20:10 IST

RECOMMENDED FOR YOU